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Self-renewal is a defining characteristic of stem
cells; however, the molecular pathways underlying
its regulation are poorly understood. Here, we dem-
onstrate that conditional inactivation of the Pbx1
proto-oncogene in the hematopoietic compartment
results in a progressive loss of long-term hematopoi-
etic stem cells (LT-HSCs) that is associated with
concomitant reduction in their quiescence, leading
to a defect in the maintenance of self-renewal as as-
sessed by serial transplantation. Transcriptional pro-
filing revealed that multiple stem cell maintenance
factors are perturbed in Pbx1-deficient LT-HSCs,
which prematurely express a large subset of genes,
including cell-cycle regulators, normally expressed
in non-self-renewing multipotent progenitors. A
significant proportion of Pbx1-dependent genes is
associated with the TGF-b pathway, which serves
a major role in maintaining HSC quiescence. Pro-
spectively isolated, Pbx1-deficient LT-HSCs display
altered transcriptional responses to TGF-b stimula-
tion in vitro, suggesting a possible mechanism
through which Pbx1 maintenance of stem cell quies-
cence may in part be achieved.
INTRODUCTION
Hematopoietic stem cells (HSCs) are distinguished by their in-
herent capacity to self-renew and differentiate into multiple
blood cell lineages throughout the life of the host. These crucial
defining attributes of HSCs must be tightly regulated and intri-
cately balanced in order to maintain homeostasis of the lym-
pho-hematopoietic system and to prevent the emergence of
blood cell malignancies.
A number of molecules have been implicated in the regula-
tion of HSC self-renewal, including cell-intrinsic transcription
factors (Tel/Etv6, Gfi1, HoxB4, c-Myc, Zfx, and FoxO1/3/4),
signal transducers (Pten), and epigenetic regulators (Bmi-1
and Ezh2), as well as extrinsic (niche-induced) factors, such as
Tek/Angpt1 and TGF-b signaling (Akala and Clarke, 2006;
Galan-Caridad et al., 2007; Kamminga et al., 2006; Tothova
et al., 2007). HSCs may also undergo various fates that prevent484 Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc.further self-renewal, including differentiation into more commit-
ted progenitor cells (inhibited by HoxB4, promoted by c-Myc),
apoptosis (inhibited by Zfx and FoxO), or senescence (inhibited
by Bmi1) (reviewed by Cellot and Sauvageau, 2007). To maintain
a steady-state pool of self-renewing cells and prevent exhaus-
tion, HSCs must limit their cell divisions and return to G0 until
the next self-renewing cycle is required. At any one time, only
a small proportion of the LT-HSC population is actually in cycle
(Venezia et al., 2004), and regulation of the ability to enter and
exit quiescence is the most critical requirement for long-term
maintenance of the stem cell pool.
Pbx1 is a TALE class homeodomain transcription factor that
critically regulates numerous embryonic processes, including
morphologic patterning, organogenesis, and hematopoiesis
(DiMartino et al., 2001; Kim et al., 2002; Manley et al., 2004;
Schnabel et al., 2003a, 2003b; Selleri et al., 2001). It is a compo-
nent of hetero-oligomeric protein complexes that regulate devel-
opmental geneexpression inpart throughmodulation ofHoxpro-
teinDNA-binding and context-dependent transcriptional effector
functions (Saleh et al., 2000). As a complex with other TALE class
proteins, Pbx1 may mark specific genes for activation by pene-
tration of repressive chromatin and recruitment of coactivators
(Berkes et al., 2004). As a major global developmental regulator,
Pbx1 has been implicated in promoting progenitor cell prolif-
eration in multiple tissues (Moens and Selleri, 2006). Its function
in adult tissue stem cells, however, is unknown, although a po-
tential role is suggested by the observation that Pbx1 is prefer-
entially expressed in LT-HSCs compared to more mature
ST-HSCs and multipotent progenitor cells (MPPs) in the hema-
topoietic system (Forsberg et al., 2005; Kiel et al., 2005).
In this report, we employed a genetic approach to condition-
ally inactivate Pbx1 in the mouse hematopoietic system in vivo.
In contrast to its role in promoting progenitor expansion, we
report that Pbx1 positively regulates HSC quiescence. Our stud-
ies demonstrate that Pbx1 is a regulator of HSC self-renewal that
contributes to maintenance of HSC quiescence through multiple
pathways, including the transcriptional program induced in
response to TGF-b signaling.
RESULTS
Postnatal Hematopoiesis Is Perturbed
in the Absence of Pbx1
Pbx1-conditional knockout (KO) mice were employed to study
the role of Pbx1 in the mouse adult hematopoietic system
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Maintenance of LT-HSC Quiescence Requires Pbx1Figure 1. Hematopoietic Defects in Pbx1-Conditional KO Mice
(A) Gross appearance is shown for spleen (top left) and thymus (bottom left) of 5-week-old representative Tie2Cre+.Pbx1+/f control and Tie2Cre+.Pbx1/fmutant
mice. Histograms on the right show the average number (±SD) of hematopoietic cells in the respective organs (*p < 0.00001, n = 14 and 27 for spleen and thymus,
respectively).
(B) Hypocellular BM in mutant mice is revealed by H&E staining of decalcified BM sections from 6-week-old mice. Histogram on the right shows average BM cell
counts as total nucleated blood cells in femurs and tibiae. Controls are Tie2Cre+.Pbx1+/f (*p = 0.005, n = 7).
(C) Histogram represents cell numbers for the indicated populations as determined by FACS analysis on BM of 3- to 4-week-old mice. Myeloid cells, CD11b+;
ProB cells, B220+CD43+IgM; PreB cells, B220+CD43IgM; immature B cells (ImmB), B220+CD43IgM+; T cells, TCRb+; NK cells, TCRbNK1.1+; and NKT
cells, TCRb+NK1.1+ (*p < 0.03; **p < 0.00004, n = 11).(Figure S1A available online). Homozygous Pbx1 floxed mice
(Pbx1f/f) were crossed with Pbx1+/ mice (Selleri et al., 2001)
expressing Cre under the control of the Tie2 promoter
(Tie2Cre+.Pbx1+/ mice), which specifically drives Cre expres-
sion in endothelial cells and HSCs (Chang et al., 2004; Kisanuki
et al., 2001). PCR analysis of the resulting Tie2Cre+.Pbx1/f
mice (referred to hereafter as ‘‘mutant’’ mice) showed specific
and complete deletion ofPbx1 in different hematopoietic tissues,
including peripheral blood (PB), bone marrow (BM), spleen, thy-
mus, and lymph nodes (Figure S1B), as expected from efficient
excision of Pbx1 in HSCs.
The hematopoietic organs appeared normal at birth, indicating
proper embryonic development, but displayed major defects in
youngmutantmice. The thymus and spleenwere dramatically re-duced in size and showedpronounced histologic disorganization
(Figure 1A and data not shown) compared to controls
(Tie2Cre+.Pbx1+/f, Tie2Cre.Pbx1+/f, or Tie2Cre.Pbx1/f mice,
which did not differ in any of the phenotypes to be described
and, hence, will not be further distinguished). Differences in the
absolute numbers of CD45+ cells betweenmutant mice and con-
trols (4-fold and 7-fold in spleen and thymus, respectively) indi-
cated that the reduced organ sizes were mainly due to a lower
content of hematopoietic cells (Figure 1A). In the thymus, FACS
analysis showed that all T-lineage cellular subpopulations were
reduced, starting from the most immature DN1 stage (data not
shown), suggesting that the defect arose at a very early stage
of T-lymphocyte development. The BM of mutant mice com-
pared to controls was hypocellular (Figure 1B), mainly accountedCell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc. 485
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Maintenance of LT-HSC Quiescence Requires Pbx1Figure 2. Decreased BM Stem and Progenitor Cells in Pbx1 Mutant Mice
(A–D) Representative FACS analyses (left) and average absolute numbers (right) of BM cells are shown for control Tie2Cre+.Pbx1+/f and mutant Tie2Cre+.Pbx1/f
mice. Numbers in the FACS plots indicate percentages among total BM cells.
(A) CLPs are defined as LinIL7R+Sca1locKitlo (Kondo et al., 1997). Depicted contour plots are referred to the LinIL7R+ gate (*p < 0.02, n = 5).
(B) FACS plots are referred to the LincKithiSca1 gate, in which CMPs are defined as CD34+/loCD16/32int, GMPs as CD34+CD16/32+, and MEPs as
CD34CD16/32 (*p < 0.005, n = 17).
(C) KSL cells are LinIL7RSca1+cKit+ (*p < 0.03, n = 7).
(D) LT-HSCs are defined as KSL, CD150+CD41CD48. FACS plots are referred to the KSL gate (*p < 0.0001, n = 10).
(E and F) Experimental outline, representative FACS analyses, and average absolute numbers of LT-HSCs in control and MxCre+.Pbx1/f mice. Indicated mice
received seven poly(I:C) injections every other day. FACS plots are referred to the KSL gate, percentages among total BM cells are indicated (*p = 0.02, n = 24). In
(F), 13 106 donor cells either from mutant or control (MxCre.Pbx1f/f) mice were transplanted into lethally irradiated Ly5.1 recipients prior to poly(I:C) injections.
KSL cells were all donor derived (*p = 0.01, n = 4).for by decreased B-lineage cells as revealed by FACS analysis
(Figure 1C). The reduction in the B cell compartment was highly
significant starting from the pro-B (B220+CD43+IgM) cell stage
with pre-B (B220+CD43IgM) cells constituting the population
numerically most reduced. Thus, Pbx1 is necessary to maintain
the postnatal hematopoietic compartment.
Lack of Pbx1 Impairs the Maintenance of Stem
and Progenitor Cells through Loss of Quiescence
FACS analyses revealed marked reduction of common lymphoid
progenitors (CLPs) (Figure 2A and Figure S2A), mild reductions in
the total numbers of common myeloid progenitors (CMPs,
Figure 2B) and to a lesser extent of granulocyte-monocyte pro-
genitors (GMPs), and reduced frequency of colony-forming cells
in semisolid culture (CFCs, Figure S2B). More importantly, there486 Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc.was a marked reduction of the HSC-enriched Linc-Kit+Sca-1+
(KSL) cell population (Figure 2C). Analysis of the LT-HSCs within
this population (Kiel et al., 2005) revealed a considerable reduc-
tion in their numbers, indicating a defect at the earliest stage of
adult hematopoietic development (Figure 2D), suggesting that
the reduction of different progenitor cell populations predomi-
nantly originated from a reduced number of LT-HSCs. The de-
scribed stem and progenitor abnormalities were progressive as
the mice aged, being undetectable at birth (Figure S2C), variable
at 2 weeks of age (in three out of five mutants analyzed), and
prominent from 3 weeks of age onward.
To rule out the possibility that a vascular niche defect to which
HSCs were exposed during development could be responsible
for the observed hematopoietic abnormalities, Pbx1f/f mice
were crossed with MxCre+.Pbx1+/ mice. Highly efficient Pbx1
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Maintenance of LT-HSC Quiescence Requires Pbx1deletion was induced with poly(I:C) in young MxCre+.Pbx1f/f
(or /f) mutant mice and confirmed by qRT-PCR 3 to 4 weeks
later (Figure S3A). Defects in the stem cell compartment of
MxCre+.Pbx1f/f (or /f) mice were identical to those observed
with Tie2Cre+.Pbx1/f mice (Figure 2E and Figure S3B), and
similar defects were also observed in CLPs, CMPs, and B cells
(Figures S3C and S3D and data not shown). To further exclude
a primary BM microenvironmental cause underlying the HSC
defect, BM cells from MxCre+.Pbx1f/f mice were transplanted
into wild-type (WT) recipients, and deletion of Pbx1 in donor cells
was induced with poly(I:C) after BM reconstitution. LT-HSCs
were reduced as a result of Pbx1 excision exclusively in
the hematopoietic compartment (Figure 2F). Furthermore,
transplant of WT BM cells into MxCre+.Pbx1f/f (or /f) mice (Fig-
ure S3E) showed that donor-derived HSCs were not reduced
upon induction of Pbx1 deletion in mutant recipient mice,
unequivocally demonstrating that the absence of Pbx1 from a
nonhematopoietic compartment does not contribute to the
HSC phenotype.
The underlying cause for reduced numbers of Pbx1 null stem
and progenitor cells was not a consequence of increased levels
of in vivo apoptosis, because Annexin V staining did not reveal
increased retention in KSL cells (data not shown), LT-HSCs (Fig-
ure S2D), or in myeloid or lymphoid progenitors (data not shown)
from mutant mice. Conversely, assessment of cellular prolifera-
tion by BrdU pulse labeling experiments revealed significantly
higher BrdU incorporation in all KSL cell subpopulations, starting
fromLT-HSCs (Figure 3A). Amore detailed analysis of the cell cy-
cle by Hoechst/Pyronin Y staining revealed that far fewer mutant
KSL and LT-HSCs were in the G0 phase, with a much higher
proportion in SG2M (Figure 3B). These data suggested that
increased proliferation likely contributes to the reduced numbers
of LT-HSCs by diminishing the pool of quiescent stem cells.
Figure 3. Pbx1-Deficient Stem Cells
Display Increased Cycling and Reduced
Quiescence
(A) Control or mutant mice were injected i.p. with
BrdU and sacrificed 2 hr later. Representative
FACS analyses on the left show BrdU and 7-AAD
incorporation in KSL cells. Graphs on the right rep-
resent the percentage of BrdU+ cells in LT-HSCs,
ST-HSCs, and MPP cells in three independent ex-
periments (*p = 0.06, **p < 0.04).
(B) Left, representative FACS analysis of PY/
Hoechst staining on KSL cells (top) or LT-HSCs
(bottom). Right, percentage of KSL cells (top) or
LT-HSCs (bottom) in G0, G1, and S phase (n = 2,
with bars representing the range).
Pbx1-Deficient HSCs Display
Intrinsic Functional Defects and
Impaired Long-Term Engraftment
In competitive repopulation assays, es-
calating doses of total BM cells from mu-
tant or control mice (Ly5.2) were infused
into lethally irradiated congenic recipi-
ents (Ly5.1), in competition with a fixed
number of BM cells from Ly5.1/Ly5.2
mice. FACS analysis of blood leukocytes
from transplanted animals revealed that BM cells from mutant
mice were completely unable to compete with WT cells even
when transplanted at a 10-fold higher dose of mutant cells
than competitor cells (Figure 4A). Donor Tie2Cre+.Pbx1/f cells
were undetectable also in the BM (data not shown). The inability
to compete withWTBMwas not simply due to a lower content of
mutant stem cells, because the same number of total BM cells
from mutant or control mice were transplanted, and the differ-
ence in the proportion of KSL and of LT-HSCs was much less
than 10-fold (Figures 2C and 2D, FACS plots). These data dem-
onstrate a profound functional impairment of LT-HSCs in the ab-
sence of Pbx1.
To assess if Pbx1-deficient stem cells are intrinsically capable
of engraftment and/or differentiation, different doses of BM cells
from mutant or control mice were infused into lethally irradiated
recipients in the absence of competitor cells. Analysis of PB for
cells of donor origin after transplant showed that, in the absence
of competition, efficient engraftment by Pbx1 null BM cells was
achieved, but only at high transplanted cell doses (Figure 4B;
only myeloid cell data are shown for simplicity, because their
high turnover provides a good measure of stem cell activity). At
lower cell doses (2 3 105 or less total BM cells), engraftment
wasmostly short term (middle and right panels) and less efficient
(right panel), in accordance with an insufficient number of func-
tional HSCs transplanted from mutant mice. Once engrafted,
multilineage differentiation was achieved (Figure S4), confirming
that differentiation and migration were not abrogated by lack of
Pbx1. PCR performed on genomic DNA isolated from donor
blood leukocytes several weeks posttransplant confirmed com-
plete excision of the floxed Pbx1 allele (Figure 4C), demonstrat-
ing that reconstitution was not mediated by rare undeleted cells
present in the BM of conditional KO mice prior to transplant.
Thus, Pbx1 null HSCs can engraft, differentiate, and reconstituteCell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc. 487
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noncompetitive conditions.
Despite engraftment by Pbx1-deficient cells, progressive graft
failure was observed long term after transplant (>20 weeks, Fig-
ure 4B), in accordance with a defect at the level of LT-HSCs.
Indeed, 20weeks after transplantwith 53 105Pbx1 null BMcells,
phenotypically defined LT-HSCs were below the limit of detec-
tion in the BMof recipient mice (Figure 4D). Accordingly, in meth-
ylcellulose in vitro colony assays performed at the same time
point, CFU-GEMM colonies were not detected after plating of
FACS-sorted (Ly5.1) donor BM cells from mice transplanted
withPbx1 null cells (Figure 4E, top) nor were any colonies derived
Figure 4. Defective Stem Cell Function in
Pbx1 Mutant Mice
(A) Total BM cells from either control (white) or
mutant (black) Ly5.2 mice were transplanted into
lethally irradiated Ly5.1 recipients in competition
with BM from Ly5.1/Ly5.2 mice, at different ratios
of donor versus competitor, as indicated at the top
of the panels. The average percentages of myeloid
(circles), B (squares), and T (triangles) cells of donor
origin in the PB of recipient mice are shown for dif-
ferent time points after transplant. The percentages
of Ly5.2+ cells were measured by FACS in the
CD11b+, B220+, and TCRb+ fractions of red blood
cell (RBC)-lysedPB.Thedataare from two indepen-
dent experiments (four to five recipients/group).
(B) Different doses of total BM cells (indicated at
top of panels) from either control or mutant Ly5.2
mice were transplanted into lethally irradiated
Ly5.1 recipients in the absence of competition.
The percentage of donor myeloid cells in the PB
of recipient mice was determined at different time
points after transplant.
(C) Representative PCR performed on the PB of
recipients of noncompetitive transplants shows
that reconstitution was mediated by cells with
complete Pbx1 deletion in mice transplanted with
mutant BM.
(D) Representative FACS analyses are shown for
HSCs at week 20 posttransplant of 5 3 105 donor
whole BM cells with two different combinations of
antibodies. Top panels, LT-HSCs are defined as
KSL,CD150+CD48; bottom panels, LT-HSCs are
defined as KSL,CD34CD135 (Mansson et al.,
2007; Rossi et al., 2005). Plots and percentages
are referred to the donor KSL gate.
(E) Methylcellulose colony assays were performed
at the time of sacrifice 20 weeks posttransplant
with BM cells of donor origin from mice that
received noncompetitive transplants.
(F) Representative FACS analyses are shown for
B cells of donor origin (Ly5.2 gate) in the BM at
week 20 after noncompetitive transplantation.
from high proliferative potential progeni-
tors (Figure 4E, bottom). Moreover, simi-
lar to theBMofmutantmice prior to trans-
plant (Figure S2), the number of total
colonies obtained was significantly re-
duced, mainly due to a decreased num-
ber of BFU-E and CFU-GM, indicating
a defect at the level of progenitors in addition to LT-HSCs, as pre-
dicted by the lower proportion and absolute number of CMP in
the conditional KO mice (Figure 2B). In the BM of recipients
transplanted with cells from Pbx1 mutants, the proportion of
B cells derived from the donor was also considerably lower
(Figure 4F). Due to their advanced age at the time of analysis,
transplanted mice exhibited small thymi and a very low propor-
tion of CLPs independent of the genotypes of the donor mice.
However, a reduced proportion of B cells in the BM (but not in
the blood) was in accordance with a progressive CLP or early B
cell progenitor defect. Hence, most of the features of the condi-
tional KO mice (low numbers of stem, progenitor, and B cells in488 Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc.
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Maintenance of LT-HSC Quiescence Requires Pbx1Figure 5. Pbx1-Deficient Cells Do Not Engraft Secondary Recipients
(A) Survival curves represent results of secondary transplants performed with donor BM cells sorted from primary recipient mice (20 weeks after primary
transplant) successfully reconstituted by control or mutant cells. Data are derived from two independent experiments containing a total of nine secondary
transplanted mice in each cohort.
(B) Representative FACS analysis of PB at 4 weeks posttransplant is shown for secondary recipients transplanted with control (left) or mutant (right, two exam-
ples) BM cells. Top, percentage of donor cells; bottom, percentage of myeloid and T cells in the donor gate. Double-negative cells are B220+ B cells (data not
shown).
(C) Summary of transplantation experiments.
(D) Survival curves after multiple 5-FU injections (indicated by arrows) of poly(I:C)-treated mutant (MxCre+.Pbx1/f or MxCre+.Pbx1f/f, n = 4) and control
(MxCre.Pbx1f/f, MxCre.Pbx1/f, or MxCre.Pbx1+/f, n = 5) mice.the BM) were reproduced in the transplanted mice and thus con-
stitute intrinsic stem and progenitor cell defects.
Pbx1-Deficient LT-HSCs Are Unable to Self-Renew
The progressive graft failure and exhaustion of mutant LT-HSCs
(KSL, CD150+CD48CD41 or KSL, CD34CD135 cells) in the
primary transplant recipients (Figure 4D) suggested a defect in
self-renewal. Therefore, secondary transplant experiments
were performed to confirm the reduction of functional Pbx1
null LT-HSCs in the BM of primary transplant recipients. Twenty
weeks after primary transplant, total BM cells from mice non-
competitively reconstituted with 5 3 105 BM cells/mouse were
harvested and sorted according to the donor Ly5.1 marker.
Sorted donor cells were then transplanted into secondary recip-
ients at escalating doses without competitor cells. Pbx1-
deficient cells were unable to engraft secondary recipients(Figure 5A). Analysis of the blood of secondary recipients before
death revealed low but detectable chimerism (Figure 5B), indi-
cating that the few HSCs originally derived from mutant mice
homed in the BMof secondary recipients but failed to fully recon-
stitute. Therefore, phenotypic and functional LT-HSCs rapidly
declined to undetectable levels after sequential transplants of
BM cells from mutant mice to primary and secondary recipients
(summarized in Figure 5C).
Hematopoietic reconstitution was also assessed in situ in
primary mutant mice by monitoring survival upon sequential
injections of the cell-cycle-dependent myelotoxic agent 5-fluo-
rouracil (5-FU) (Cheng et al., 2000), an assay that does not
depend on engraftment. The requirement for a relatively long fol-
low-up prompted the use of the MxCre conditional KO model,
because Tie2Cre+.Pbx1/f mice have a short life span. Five
weeks after the last poly(I:C) injection, mutant and control miceCell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc. 489
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Maintenance of LT-HSC Quiescence Requires Pbx1Figure 6. Gene Expression Profile of Pbx1-Deficient HSCs
(A) Heat map shows the expression of the 241 Pbx1-regulated genes in LT-HSCs from poly(I:C)-treated control (MxCre.Pbx1f/f, C1, and C2) or mutant
(MxCre+.Pbx1f/f, M1–M3) individual mice. Upregulated and downregulated genes are presented in red and blue, respectively.
(B) Pie charts show the distribution of the 61 upregulated (top) and the 180 downregulated (bottom) genes in Pbx1-deficient LT-HSCs into functional groups.
(C) Heat map displays the differentially expressed transcripts in LT- and ST-HSCs from poly(I:C)-treated control mice.
(D) Pie charts represent the overlap of themutant LT-HSC gene signature with genes found in the current study to be differentially expressed in the LT- to ST-HSC
transition in control mice (17% and 37% for the downregulated and upregulated genes, respectively), as well as with genes differentially expressed in the LT-HSC
to MPP transition not included in the LT/ST-HSC overlap (14% and 11%).490 Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc.
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ing hematopoietic progenitors, thus providing a stimulus for
HSCs to proliferate in order to replenish the hematopoietic
system. Pbx1-deficient mice succumbed after the second 5-FU
injection, whereas exhaustion of the HSC pool occurred signi-
ficantly later in control mice (Figure 5D). Mutant mice died of
hematopoietic failure, with pancytopenia in the blood and BM
(data not shown).
Taken together, our data demonstrate that Pbx1maintains the
hematopoietic system by regulating LT-HSC self-renewal.
A Pbx1-Dependent Transcriptional Program Implicates
Perturbation of Multiple Pathways in Loss of LT-HSC
Quiescence and Self-Renewal
Global gene expression profiling analyses were performed to
identify Pbx1-dependent genes and pathways involved in the
regulation of HSC self-renewal. For these studies, Pbx1 deletion
was induced in MxCre+.Pbx1f/f mutant mice, which allowed the
use of older animals to obtain a much higher yield of LT-HSCs
and also the distinction between LT- and ST-HSCs in adult
mice based on the expression of CD34 and CD135 markers in
KSL cells. Cells were prospectively sorted from BM harvested
4 weeks after the last injection of poly(I:C).
Analysis of gene expression data from mutant and control
LT-HSCs revealed 241 nonredundant differentially expressed
genes, of which 61 were upregulated and 180 downregulated in
Pbx1mutants (Figure 6A and Table S1). Microarray results were
confirmed by qRT-PCR for a small subset of the genes (Table
S1). Classification based on functional annotation revealed that
a large proportion of upregulated genes in Pbx1 mutant LT-
HSCs belonged to cell-cycle ontogeny groups (Figure 6B), con-
sistent with the observed increase in cycling stem cells leading
to loss of their self-renewal potential. Notably,8%of the down-
regulated genes belonged to the TGF-b signaling pathway (Fig-
ure 6B and Table S2), which has been previously implicated in
maintenance of HSC quiescence. Other differentially regulated
transcripts included genes known to be involved in self-renewal
of HSCs (Hlf and Meis1) or to have roles in differentiation, the
ubiquitin pathway, cell adhesion, chromatin modification, and
various signaling pathways, including the MAPK pathway, which
has been implicated in HSC maintenance (Ito et al., 2006). Thus,
the transcriptional changes suggest thatmultiple stemcell-main-
tenance mechanisms are perturbed in the absence of Pbx1.
The lack of long-term self-renewal but preserved reconstitu-
tion potential, as well as increased proliferation, suggested that
phenotypically defined Pbx1-deficient LT-HSCs display func-
tional features of ST-HSCs and/or MPPs. To test this hypothesis,
the Pbx1 mutant LT-HSC gene set was interrogated for genes
whose expression normally distinguishes LT- from ST-HSCs.
To generate the latter gene set, LT- and ST-HSCs were prospec-
tively sorted from the BM of WT mice and their global gene
expression profiles were determined by microarray (Figure 6C).
Bioinformatic analysis revealed a gene set of 2468 nonredundant
transcripts that were differentially expressed between normal
LT- and ST-HSCs subpopulations (Table S3), a higher numberthan previously reported by using different sorting and analysis
strategies (Forsberg et al., 2005; Zhong et al., 2005). This gene
set (LT- versus ST-HSCs) was then compared with the Pbx1-de-
pendent LT-HSCs gene set. Among the transcripts down-
regulated in mutant LT-HSCs, 17% were also downregulated
in normal ST-HSCs compared to LT-HSCs. Furthermore, among
the transcripts upregulated in mutant LT-HSCs, a substantial
proportion (37%) was also upregulated in normal ST-HSCs.
Thus, many of the genes aberrantly expressed in phenotypically
defined LT-HSCs fromPbx1mutantmice are normally expressed
in ST-HSCs, but not WT LT-HSCs. The mutant LT-HSC gene
signature was also compared with a previously published gene
set differentially expressed in MPPs versus LT-HSCs (Kiel et al.,
2005). A considerable overlap was observed between Pbx1
mutant LT-HSC and normal MPP gene expression profiles
(Figure 6D), further confirming that, in the absence of Pbx1,
LT-HSCs prematurely express a transcriptional subprogram
shared with downstream ST-HSCs and MPPs.
The functional and expression profiling studies suggested that
Pbx1 regulates stem cell quiescence and exit from the LT self-
renewing compartment. To further test this hypothesis, Gene
Set Enrichment Analysis (GSEA) was employed to compare the
Pbx1-regulated dataset with curated gene sets derived from
diverse published experiments (Subramanian et al., 2005). To
query the curated gene sets, the Pbx1-regulated dataset was
reduced to a rank-ordered list of genes expressed by mutant
versusWT LT-HSCs (more than 9684 nonredundant transcripts).
In accordance with our hypothesis, GSEA revealed a strong cor-
relation of genes downregulated in the absence of Pbx1 with
gene sets that identify HSCs (Table 1 and Figure 6E). Conversely,
the genes upregulated in the absence of Pbx1 strongly corre-
lated with gene sets typical of progenitors (Table 1 and Fig-
ure 6E), as well as with cell-cycle-related gene sets. GSEA also
revealed enrichment for Myc-activated genes and for genes in-
volved in DNA damage control, possibly related to the perturbed
cell-cycle status of Pbx1mutant LT-HSCs. Of note, genes down-
regulated in the absence of Pbx1 were also enriched for B cell
gene sets, indicating that the CLPs and B cell abnormalities
observed in mutant mice most likely originated from a LT-HSC
defect in lymphoid priming.
Absence of Pbx1 Alters the Transcriptional Response
to TGF-b in LT-HSCs
GSEA also confirmed a prominent perturbation of the TGF-b
pathway in Pbx1 mutant LT-HSCs as evidenced by significant
enrichment of gene sets associated with TGF-b pathway alter-
ations in various cell types (Table 1), including human cord blood
CD34+ cells exposed to TGF-b in vitro (Figure 6E). Therefore, the
integrity of the TGF-b signaling pathway was interrogated in pro-
spectively purified mutant and WT LT-HSCs by assessing their
transcriptional responses to TGF-b stimulation in vitro. In con-
trast to WT LT-HSCs, mutant LT-HSCs did not upregulate
expression of several downstream transcripts in response to
TGF-b stimulation (Figure 6F), including Smad7, Klf4, and Ski,
as well as Cdkn1c (p57), recently implicated as an important(E) Enrichment plots of selected gene sets from the GSEA in Table 1.
(F) Histogram shows fold induction for the indicated transcripts in sorted LT-HSCs upon 4 hr of TGF-b exposure, asmeasured by qRT-PCR (**p < 0.0001, *p% 0.01;
p57: n = 7 mutants and 8 controls; Smad7: n = 3; Klf4, Ski: n = 4 mutants and 2 controls; Ccnd2, Ccna2: n = 4 and 3 mutants, respectively, and one control).Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc. 491
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Gene Set Name FDR Gene Set Description
Downregulated Genes
HSC Gene Sets
HSC_LTHSC_FETAL 0.16 Upregulated in mouse LT-HSCs from fetal liver (FL)
HSC_LTHSC_SHARED 0.16 Upregulated in mouse LT-HSCs from both adult BM and FL
HSC_LTHSC_ADULT 0.18 Upregulated in mouse LT-HSCs from adult BM
HSC_HSCANDPROG_FETAL 0.18 Upregulated in mouse HSCs and progenitors from FL
FETAL_LIV_ENRICHED_TF 0.18 Transcription factors enriched in human fetal liver
HSC_HSCANDPROG_ADULT 0.18 Upregulated in mouse HSCs and progenitors from adult BM
HEMATOP_STEM_ALL_UP 0.22 Upregulated in human HSCs (CD34+/CD38/Lin) versus CD34+/CD38+/Lin+
ROSSI_AGING_UP 0.00 Upregulated in LT-HSCs from aging mice (= higher self-renewal) (Rossi et al., 2005)
FICARA_LTHSC_UP 0.00 Upregulated in WT LT-HSCs versus ST-HSCs (this study)
KIEL_LTHSC_UP 0.04 Upregulated in WT LT-HSCs versus MPP (Kiel et al., 2005)
TGF-b Gene Sets
EMT_DN 0.17 Downregulated in the TGF-b-induced epithelial-to-mesenchymal transition
TGF_BETA_SIGNALING_PATH 0.18 Genes in the TGF-b signaling pathway
RUTELLA_HGHSNDCS_UP 0.22 Genes upregulated by HGF treatments (monocyte to TGF-b-producing DC)
SCANDURA_TGFBCD34_UP 0.00 Upregulated in hCB CD34+ cells treated with TGF-b (Scandura et al., 2004)
B Cells Gene Sets
HADDAD_CD45CD7_PvsM_DN 0.00 Genes enriched in CD45RAintCD7 versus CD45RAhiCD7hi HPCs
HADDAD_HSC_CD7_DN 0.00 Upregulated in human hHSCs of the line CD45RAintCD7 versus CD45RAhiCD7+
HADDAD_HSC_CD10_UP 0.18 Upregulated in hHSC CD45RAhiLinCD10+ versus CD45RAintCD7 and CD45RAhiCD7+
HOFFMAN_BIVSBII_LGBII 0.23 Genes with 5-fold change in expression between large and small Pre-BII
HADDAD_HPCLYMPHO_ENRIC 0.22 Enriched in CD45RAhiLinCD10+ versus CD45RAintCD7 and CD45RAhiCD7hi
SIG_PIP3_SIGNALING_IN_B_L 0.23 Genes related to PIP3 signaling in B lymphocytes (SignalingAlliance)
C/EBP Gene Sets
GERY_CEBP_TARGETS 0.05 Complete list of differentially regulated C/EBP-target genes
TAVOR_CEBP_UP 0.23 C/EBP upregulated genes in KCL22 cells
Upregulated Genes
Cell-Cycle Gene Sets
SERUM_FIBROBL_CELLCYCLE 0.00 Cell-cycle-dependent genes regulated after exposure to serum
CROONQUIST_IL6_STARV_UP 0.00 Upregulated in multiple myeloma cells exposed to IL-6
DNA_REPLICATION_REACT 0.00 http://www.genmapp.org
GOLDRATH_CELLCYCLE 0.00 Cell-cycle genes induced during antigen activation of CD8+ T cells
CELL_CYCLE 0.00 Progression of events that occur during replication (GO)
CELL_CYCLE_KEGG 0.00 http://www.genmapp.org
BRENTANI_CELL CYCLE 0.00 Cancer-related genes involved in the cell cycle (Broad Institute)
CELL_CYCLE_CHECKPOINT 0.00 Point where progress through the cycle can be halted (GO)
G2PATHWAY 0.02 Biocarta
G1toS_ CELL_CYCLE_REACT 0.02 http://www.genmapp.org
Myc Gene Sets
YU_CMYC_UP 0.00 Myc-activated genes
COLLER_MYC_UP 0.01 Genes upregulated by MYC in 293T
SCHUMACHER_MYC_UP 0.01 Genes upregulated by MYC in P493-6
ZELLER_MYC_UP 0.05 Genes upregulated by MYC in >3 papers
MYC_TARGETS 0.09 Myc-responsive genes reported in multiple systems
ST-HSC/Progenitors Gene Sets
HSC_LATEPROG_FETAL 0.01 Upregulated in mouse hematopoietic late progenitors from FL
HSC_LATEPROG_ADULT 0.01 Upregulated in mouse hematopoietic late progenitors from adult BM
HSC_LATEPROG_SHARED 0.01 Upregulated in mouse hematopoietic late progenitors from both adult BM and FL
HSC_INTERMPROG_FETAL 0.19 Upregulated in mouse hematopoietic intermediate progenitors from FL492 Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc.
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Gene Set Name FDR Gene Set Description
Downregulated Genes
HSC_INTERMPROG_SHARED 0.21 Upregulated in mouse hematopoietic intermed progenitors from adult BM and FL
FICARA_STHSC_UP 0.00 Upregulated in WT ST-HSCs versus LT-HSCs (this study)
ID1_KO_UP 0.00 Upregulated in Id1-KO mice (= progenitor phenotype) (Jankovic et al., 2007)
ROSSI_AGING_DOWN 0.01 Upregulated in LT-HSCs from young mice (= lower self-renewal)
Ubiquitin Pathway
PROTEASOMEPATHWAY 0.10 www.broad.mit.edu/gsea/msigdb/cards/PROTEASOMEPATHWAY.html
PROTEASOMEDEGRADATION 0.19 Curated by Broad Institute
DNA Damage Control
ATMPATHWAY 0.03 The protein kinase ATM responds to radiation-induced DNA damage
FERRANDO_MLL_T_ALL_DN 0.03 Cancer-related genes involved in DNA repair
DNA_DAMAGE_SIGNALING 0.07 Genes involved in DNA damage signaling (Broad Institute)
UVB_SCC_UP 0.14 Upregulated by UV-B light in squamous cell carcinoma cells
ROTH_HTERT_DIFF 0.24 Involved in DNA repair and cell-cycle control in hTERT-transduced cells
Gene sets in italic do not belong to the GSEA data set; they have been curated by F.F. et al.regulator of HSC quiescence (Scandura et al., 2004; Umemoto
et al., 2005; Yamazaki et al., 2006). Furthermore, unlike control
LT-HSCs, Ccnd2 and Ccna2 were not downregulated by TGF-b
simulation inmutant LT-HSCs, consistent with their in vivo cycling
activity. These results together with the global transcriptional
changes suggest that Pbx1 controls stem cell quiescence and
self-renewal at least in part by affecting the response to TGF-b.
DISCUSSION
In this study, we demonstrate that the Pbx1 proto-oncogene and
global developmental regulator serves a critical role within the
hematopoietic system to support the self-renewal of adult
HSCs as one of few known factors involved in maintaining their
quiescence. Transcriptional profiling suggests that multiple
stem cell maintenance programs are perturbed in the absence
of Pbx1, including genes associated with the response to TGF-
b signaling. This suggests potential mechanisms for facilitating
loss of quiescence, inappropriate cell-cycle entry, and initiation
of a transcriptional program resembling that of morematuremul-
tipotent progenitors. As a consequence, LT-HSCs lose their ma-
jor defining characteristic, i.e., self-renewal, and progressively
exhaust themselves in the absence of Pbx1.
Among the multiple stem cell maintenance factors that are
altered in Pbx1-deficient LT-HSCs, a significant proportion are
linked with the TGF-b pathway, which is increasingly implicated
in regulation of HSC quiescence. TGF-b has recently been sug-
gested as a possible BM niche signal necessary to induce LT-
HSC ‘‘hibernation’’ through inhibition of lipid raft clustering in
response to cytokine stimulation (Yamazaki et al., 2007). The
CDKI p57 appears to be responsible for regulating this quiescent
HSC state (Yamazaki et al., 2007). Consistent with these obser-
vations, cell-cycle arrest of human cord blood CD34+ cells in
response to TGF-b requires p57 (Scandura et al., 2004). More-
over, p57 is responsible for cell-cycle arrest of mouse KSL side
population (SP) cells (Umemoto et al., 2005), suggesting that it
is one of the main contributors to maintenance of LT-HSC quies-
cence. We observed higher expression levels of Cdkn1c inLT-HSCs compared to ST-HSCs (although the difference did
not meet our stringent statistical requirements for inclusion in
Table S3). This is consistent with previous studies performed
with different methods and mouse strains showing that Cdkn1c
is preferentially expressed in LT-HSCs compared to ST-HSCs
and MPPs (Kiel et al., 2005) and at higher baseline levels in
mouseCD34KSL cells (highly enriched for LT-HSCs) than other
CDKIs such as p21 or p27 (Yamazaki et al., 2006). Although the
latter are also implicated in HSC or progenitor self-renewal, we
did not observe their expression levels to be altered in Pbx1-
deficient LT-HSCs in contrast to the marked reduction in p57.
In support of a possible role for Pbx1 on a pathway that regu-
lates the balance between stem cell quiescence/hibernation and
cell-cycle entry, the Cdkn1c gene was not induced by TGF-b
stimulation of prospectively isolated Pbx1 mutant LT-HSCs. Al-
though these data do not rule out a secondary role for Cdkn1c,
it is one of very few in our Pbx1-dependent gene set to contain
a Pbx1 heterodimer binding site in proximity to its promoter. Fur-
thermore, Pbx1/Prep transcriptional complexes have been
shown to interact with Smads (Bailey et al., 2004), the nuclear ef-
fectors of TGF-b signaling, and Pbx1 transcriptional complexes
regulate expression of the p21 gene in a myelomonocytic cell
line (Bromleigh and Freedman, 2000). In epithelial cells, a
FoxO/Smad complex is implicated in TGF-b upregulation of
p15ink4a, another CDKI (Gomis et al., 2006). Thus, there are
precedents for regulation of CDKI genes by Pbx and/or Smad
proteins. However, perturbed expression of Smad7, a TGF-b
pathway regulator that has been implicated in HSC self-renewal
(Blank et al., 2006), was also observed in Pbx1-deficient HSCs
in vitro and in vivo, raising the possibility of a more global com-
promise of the response to TGF-b. Because our data were
obtained 4 weeks after Pbx1 deletion, it is theoretically possible
that they reflect in part compensatory changes in the prolifera-
tion activity or differentiation state of the stem cell compartment.
Further investigations are necessary to establish a causal rela-
tionship between the hematopoietic defects caused by Pbx1
loss and perturbed regulation of TGF-b pathway-associated
genes implicated in HSC self-renewal.Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc. 493
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only apparent from 3 weeks postbirth despite the fact that
expression of the Tie2Cre transgene initiates in definitive HSCs
with their emergence in the aorta-gonad-mesonephros and
yolk sac during embryonic development. The postnatal onset
of the Pbx1 phenotype likely reflects differences in the prolifera-
tion states of embryonic/fetal and adult BM HSCs. During devel-
opment, HSCs undergo massive expansion while preserving
their self-renewal capacity, whereas HSCs in the postnatal BM
are mostly quiescent starting from 3–4 weeks of age (Bowie
et al., 2006), and their ability to maintain quiescence correlates
with the maintenance of self-renewal and engraftment potential
(Passegue et al., 2005). Thus, onset of the Pbx1-deficient HSC
phenotype in Tie2Cre.Pbx1 mice correlates with the postnatal
requirement for HSC quiescence for maintenance of self-
renewal.
A role for Pbx1 in maintaining stem cell quiescence signifi-
cantly broadens its contributions beyond previous studies,
which have consistently implicated it in promoting progenitor
cell expansion during development of multiple organs (Brendo-
lan et al., 2005; Kim et al., 2002; Manley et al., 2004; Selleri
et al., 2001), including the hematopoietic system (DiMartino
et al., 2001). Thus, Pbx1 appears to have divergent but function-
ally complementary roles in the maintenance of HSC quiescence
versus promotion of progenitor proliferation, and our current re-
sults raise the possibility that other Pbx1-deficient phenotypes
may in part reflect its impact on tissue-specific stem cells. The
potential complexity of its contributions in the hematopoietic
progenitor compartment was suggested by earlier studies dem-
onstrating that HoxB4-mediated HSC in vitro expansion is fur-
ther enhanced by concurrent reduction of Pbx1 expression
(Krosl et al., 2003), which appeared inconsistent with its role
in promoting progenitor expansion. However, a major function
for Pbx1 in maintaining LT-HSC quiescence provides a likely
explanation for its antagonistic effects because HoxB4 overex-
pression enhances HSC expansion without affecting long-term
self-renewal potential. The divergent roles for Pbx1 in HSCs
versus progenitors may reflect possible context-dependent con-
tributions to the expression of CDKI and other cell-cycle regula-
tory genes.
In addition to a stem cell defect, a marked reduction was ob-
served in the BM pro- and pre-B cell compartments, as well as
a striking reduction in CLPs, suggesting a role for Pbx1 at
a critical stage of lymphoid development where acute leukemia
likely originates and confirming previous results from our labora-
tory obtained with a different experimental approach (Sanyal
et al., 2007). The extremely low number of CLPs in mutant
mice prevented studies of their cell-cycle status, although the
cycling rates of pro- and pre-B cells were only mildly decreased
(data not shown), consistent with previous conclusions that Pbx1
may be dispensable from the pro-B stage onward (Sanyal et al.,
2007). The striking CLP hypoplasia may reflect a cell-intrinsic re-
quirement for Pbx1 in CLPs or alternatively be the consequence
of insufficient CLP generation due to an aberrant differentiation
program initiated by Pbx1 null HSCs. In support of the latter,
GSEA revealed a defect in lymphoid priming present at the
LT-HSC stage. The expression of lymphoid-specific genes in
LT-HSCs and the concept of lineage priming in stem cells have
been previously reported (Mansson et al., 2007; Rossi et al.,494 Cell Stem Cell 2, 484–496, May 2008 ª2008 Elsevier Inc.2005). In Pbx1-deficient mice, the lymphoid priming defect
does not completely compromise further differentiation capac-
ity, because mature B cells are present in BM, spleen, and PB
of primary KO mice and transplant recipients. In future studies,
it will be of interest to further characterize the roles of Pbx1 in
HSC lymphoid priming and generation of CLPs and the potential
relevance of these contributions for Pbx1 oncoproteins in B cell
precursor leukemias.
EXPERIMENTAL PROCEDURES
Mice
Transgenic Tie2Cre,Mx1Cre, and Pbx1+/ mice have been described (Chang
et al., 2004; Kisanuki et al., 2001; Kuhn et al., 1995; Selleri et al., 2001). These
strains were intercrossed to generate Tie2Cre+.Pbx1+/ or MxCre+.Pbx1+/
mice, which were subsequently bred with Pbx1f/f mice (to be described
elsewhere) to obtain Tie2Cre+.Pbx1/f, MxCre+.Pbx1/f, or MxCre+.Pbx1f/f
mutants and their littermate controls, fully or partially backcrossed onto
a C57BL/6 background. Mutant and control mice were genotyped by PCR.
Tie2Cre+.Pbx1/f were viable but displayed a short life span and died of
unknown causes between 3 and 7 weeks of age. Congenic Ly5.1 mice, pur-
chased from Jackson Laboratories (Bar Harbor, ME), were maintained in the
Stanford animal facility and used as recipients of BM transplantation experi-
ments. Congenic C57BL/6 Ly5.2 mice were crossed with Ly5.1 mice to obtain
Ly5.1/Ly5.2 competitor BM cells. All experiments were performed with the
approval of and in accordance with Stanford’s Administrative Panel on Labo-
ratory Animal Care.
Histology
Tissues were fixed in 10% (weight/volume) formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin.
Flow Cytometry
BM cell suspensions were obtained by flushing of femurs and tibiae in sterile
staining buffer (see below). PB was obtained by tail bleeding. Staining of cells
for FACS analysis was performed in deficient RPMI (Irvine Scientific) contain-
ing 3% fetal calf serum, 1 mM EDTA, and 0.01 M HEPES (staining buffer) with
the following conjugated monoclonal antibodies (mAbs) obtained from either
BD PharMingen (BD) or eBioscience (San Diego, CA): Mac1/CD11b (M1/70),
B220 (RA3-6B2), CD43 (S7), IgMb (AF6-78), TCRb (H57-597), NK1.1 (PK136),
TER119 (TER-119), c-Kit (2B8), Sca1 (D7 or E13-161.7), IL-7Ra (SB14),
CD16/32 (2.4G3), CD34 (RAM34), CD48 (HM48-1), CD41 (MWReg30), Ly5.1
(A20), Ly5.2 (104), and CD135 (AF2 10.1). The lineage cocktail included the
following Cy7PE-conjugated mAbs: Mac1, Gr1 (RB6-8C5), B220, TER119,
CD3 (145-2C12), CD4 (GK1.5), and CD8 (53-6.7). CD150 (TC15-12F12.2)
was purchased from BioLegend. Stained cells were analyzed with an LSR1A
flow cytometer or FACSAria (BD Biosciences, San Jose, CA). Cell sorts were
performed with a FACSVantage (BD Biosciences). Cell Quest Pro or Diva soft-
ware (BD) and FlowJo (Tree Star) were used for data acquisition and analysis,
respectively. For Annexin V staining, freshly isolated BMcells were first stained
with the appropriate mAbs, then washed in binding buffer and incubated with
Annexin V FITC (BD).
Cell-Cycle Analysis
Mice received a single intraperitoneal injection of 5-bromodeoxyuridine (BrdU)
2 hr prior to sacrifice. In order to have enough cells for the analysis of LT-HSCs,
BM cells were obtained by the crushing of multiple bones (femurs, tibia,
humerous, ulna, shoulder blades, sternum, and spine). Progenitors were puri-
fied based on the expression of c-Kit by using anti-CD117 magnetic micro-
beads and an automated cell separator (AutoMACS, Miltenyi Biotec, Auburn,
CA) and then subjected to cell surface staining for detection of stem cells.
Analysis of BrdU incorporation was performed with the FITC BrdU Flow Kit
(BD PharMingen) according to the manufacturer’s protocol. For H/PY staining,
purified c-Kit+ cells were incubated with cell surface markers to detect HSCs
and then incubated with HOECHST 33342 (Invitrogen) and Pyronin Y (Sigma-
Aldrich) as previously described (Passegue et al., 2005).
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Transplantation of BM cells from mutant or control mice (with or without 2 3
105 competitor BM cells), or secondary transplantation of donor-derived BM
cells from primary recipients, was performed by retro-orbital injection of
lethally irradiated Ly5.1 mice (900 cGy). For secondary transplants, three
doses of sorted Ly5.2 cells were injected: 13 106, 53 105, and 23 105 (three
mice/group). Data from the three different doses were pooled because the
outcome did not correlate with the number of injected cells.
5-FU Treatment
Two-week-old MxCre+.Pbx1f/f (or /f) or control mice received poly(I:C) injec-
tions (InvivoGen, San Diego, CA) every other day for a total of seven injections.
Five weeks after the last injection, mice received 150 mg/kg 5-FU (ICN
Pharmaceuticals, Inc., Costa Mesa, CA) i.p. at 7 day intervals.
Colony-Forming Unit Assays
BM cells (2 3 104) were seeded into methylcellulose-containing medium
(methoCult 3234; Stem Cell Technologies) in the presence of SCF (20 ng/ml),
IL-6, IL-3 (10 ng/ml each), and Epo (3 U/ml). Colonies were counted after
10 days of culture.
Statistical Analysis
The significance of differences was determined by two-tailed Student’s t test.
Microarray and Bioinformatics Analyses
Two-week-old MxCre+.Pbx1f/f or MxCre.Pbx1f/f mice were given seven
poly(I:C) injections every other day and sacrificed 4 weeks after the last injec-
tion. BM cells were obtained from multiple bones of individual mice, immuno-
magnetically selected for c-Kit expression, then stained with conjugatedmAbs
(CD34, CD135, Sca-1, lineage cocktail, and c-Kit) prior to sorting. Cells were
maintained on ice when possible through all procedures. RNA from sorted
cell populations (3–5000 LT-HSCs, 4–12,000 ST-HSCs) was purifiedwith Trizol
and subjected to two rounds of amplification with a Two-Cycle Target Labeling
and Control Reagent (Affymetrix, Santa Clara). Microarray experiments were
performed in the Stanford PAN Facility with Affymetrix 430-2.0 arrays. Arrays
were scannedwith aGeneChip Scanner 3000 (Affymetrix) runningGCOS 1.1.1
software. Scanned data were exported to dChip software for normalization,
statistical analysis, and heat mapping. A perfect-match/mismatch (PM/MM)
model was used for the calculation of expression values (Li and Wong,
2001). The threshold for considering genes differentially expressed was 1.3-
fold difference with a 90% confidence. Raw data are available for download
fromGene Expression Omnibus (http://ncbi.nlm.nih.gov/geo). The categoriza-
tion of genes into functional groupings was based on the Gene Ontology (GO)
classification system as well as on comprehensive evaluation of the relevant
literature for all of the differentially regulated genes. Gene set enrichment
analysis (Subramanian et al., 2005) was performed with GSEA v2.0 software
available from the Broad Institute (http://www.broad.mit.edu/gsea).
Real-Time Quantitative PCR
For studies of TGF-b-dependent transcriptional response, LT-HSCs were
sorted from poly(I:C)-treated MxCre+Pbx1f/f or control mice as described for
the microarray experiments and then incubated for 4 hr in StemPro-34SFM
medium (GIBCO) with 2 ng/ml TGF-b1 (PeproTech, Rocky Hill, NJ) prior to
RNA extraction with a PicoPure RNA Isolation Kit (Arcturus, Mountain View,
CA) and amplification with a RiboAmp RNA Amplification Kit (Arcturus).
cDNA was prepared with Superscript First-Strand Synthesis System for
RT-PCR (Invitrogen, Carlsbad, CA) and then subjected to real-time PCR with
TaqMan probes (Applied Biosystems, Foster City, CA).
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